drugset / Trial / NCT05856084
Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above
Phase 2
Active not recruiting
924 enrolled
MAXVAX Biotechnology Limited Liability Company
Henan Center for Disease Control and Prevention · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purposes of the study are to evaluate the immunogenicity and safety of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 30 years and older.
Timeline
- Start
- 2023-05-07
- Primary completion
- 2024-12-28
- Completion
- 2026-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant Herpes Zoster Vaccine (CHO cells) | Vaccine | 50 ug | Intramuscular |
| Subject | Recombinant Herpes Zoster Vaccine (CHO cells) | Vaccine | 0.5 ml | Intramuscular |
| Comparator | Shingrix | Vaccine | 50 ug | Intramuscular |
| Comparator | Shingrix | Vaccine | 0.5 ml | Intramuscular |